Elevated autoantibodies against dipeptidyl peptidase-4 are associated with poor prognosis in patients with type 2 diabetes
Open Access
- 1 January 2026
- journal article
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73 (11) , 1185-1191
Abstract
Dipeptidyl peptidase-4 (DPP4) is involved in immune regulation and metabolic homeostasis. Although DPP4 inhibitors are widely used in type 2 diabetes, the clinical relevance of autoantibodies against DPP4 (DPP4-Ab) remains unclear. In this study, we aimed to investigate the association between circulating DPP4-Ab levels and mortality in 274 patients with type 2 diabetes (mean age, 63 years). Serum DPP4-Ab levels were measured using amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA), and survival was assessed using Kaplan-Meier analysis and Cox proportional hazards regression analysis. During a mean follow-up of approximately 5 years, 32 deaths had occurred. Patients with elevated DPP4-Ab titers (>1,676.8 alpha counts) had a higher mortality rate than those with low titers (22.2% vs. 9.3%, p = 0.0177). In Cox proportional hazards regression analysis, DPP4-Ab titers showed a trend toward association with all-cause mortality when analyzed as a continuous variable per 100 alpha counts (a.c.) increase (hazard ratio [HR], 1.042; 95% confidence interval [CI], 0.996–1.090; p = 0.071). When patients were stratified using the predefined cutoff value of 1,676.8 a.c., the high DPP4-Ab group showed significantly higher mortality risk than the low DPP4-Ab group (HR, 2.30; 95% CI, 1.09–4.84; p = 0.028). Addition of DPP4-Ab to an age-based model only slightly improved predictive discrimination. These findings suggest that elevated DPP4-Ab titers may be associated with mortality risk; however, this association should be interpreted cautiously and warrants further investigation as a potential adjunctive immunometabolic biomarker in type 2 diabetes.Keywords
Funding Information
- Japan Society for the Promotion of Science (23K06889)
- Japan Society for the Promotion of Science (24K10559)
This publication has 17 references indexed in Scilit:
- Increased autoantibodies against incretin indicate poor prognosis in patients with diabetesScientific Reports, 2025
- Impact of dipeptidyl peptidase-4 inhibitors on incidence of colorectal cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysisTherapeutic Advances in Drug Safety, 2025
- Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosisScientific Reports, 2021
- Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic strokeBMC Medicine, 2021
- Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 DiabetesJAMA, 2019
- Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune systemClinical and Experimental Immunology, 2016
- Sitagliptin use and thyroid cancer risk in patients with type 2 diabetesOncotarget, 2016
- Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 InhibitorsEndocrine Reviews, 2014
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 2013
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 DiabetesNew England Journal of Medicine, 2013